Wockhardt Ltd.WOCKPHARMA₹1,564.40 +17.05%

Shares of Wockhardt Ltd. surged on relief from the US tariff announced by President Trump, reaching an intraday high of ₹1,588.00 apiece. The US tariff will be exempt for countries with existing trade agreements, such as the European Union and Japan. 

This exemption is critical for Wockhardt, which derives nearly 78 percent of its global revenue from international businesses and holds significant manufacturing assets in Europe, including its injectable facility in North Wales, UK, and capacity acquired through the French firm Negma. 

This positioning ensures that key products, such as its flagship antibiotic Zaynich, manufactured in Europe for the US market, are shielded from the punitive 100% duty, mitigating a major risk that had initially depressed the stock.

The overall impact on the Indian pharma sector is also limited because of its dominant focus on the generics market. India exports about $8.7 billion worth of pharmaceuticals to the US, and since generic drugs constitute 90% of US drug volumes, they are largely unaffected by the tariff. However, the 100% tariff on imported branded drugs is still raising costs, which risks price hikes and supply disruptions in that segment.

Over the last three and five years, this stock has delivered multibagger returns of more than 555% and 455%, respectively. 

Let’s take a look at its Factor Analysis scores:

Note: The stock prices mentioned are as of 3:30 pm.

Disclaimer and Disclosure 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing. Registration granted by SEBI, enlistment as Research Analyst with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Kindly refer to  https://share.market/ for more details.Investments in WealthBaskets are subject to the Terms of Service. All investors are advised to conduct their own independent research into investment strategies before making an investment decision. PPWB acts as a distributor of mutual funds and it is not an exchange traded product. PPWB acts as a distributor of mutual funds and WealthBaskets and it is not an exchange traded product. Disputes with respect to the distribution activity of Mutual Funds and WealthBaskets will not have access to Exchange investor redressal or Arbitration mechanism. The securities are quoted as an example and not as a recommendation. This is for informational purposes and should not be considered as recommendations.

PhonePe Wealth Broking Private Limited is a member of NSE & BSE with SEBI Regn. No.: INZ000302639, Depository Participant of CDSL Depository with SEBI Regn. No.: IN-DP-696-2022, Research Analyst with SEBI Regn No: INH000013387, BSE RA Enlistment Number: 5887 and Mutual Fund distributor with AMFI Registration No: ARN- 187821. Member ID: BSE- 6756, NSE- 90226. Registered office – 2, Floor 3, Wing A, Block A, Salarpuria Softzone, Service Road, Green Glen Layout, Bellandur, Bengaluru South, Bengaluru, Karnataka – 560103, INDIA. CIN: U65990KA2021PTC146954